Retrospective analysis of imaging and clinical features from patients treated with brolucizumab in post-marketing setting with reports of intraocular inflammation and/or retinal vascular occlusion First published 11/05/2021 Last updated 23/04/2024 EU PAS number:EUPAS41014 Study Finalised